Minimal residual disease in multiple myeloma: Benefits of flow cytometry

E-ISSN： 1751-553x|40|1|12-20

ISSN： 1751-5521

Source： International Journal Of Laboratory Hematology, Vol.40, Iss.1, 2018-02, pp. : 12-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma

By Fenk Roland Haas Rainer Kronenwett Ralf

Hematology, Vol. 9, Iss. 1, 2004-02 ,pp. : 17-33

Maney Publishing

Access to resources Recommend Favorite

Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay

By Rasmussen T. Poulsen T.S. Honore L. Johnsen H.E.

Experimental Hematology, Vol. 28, Iss. 9, 2000-09 ,pp. : 1039-1045

Elsevier

Access to resources Recommend Favorite

Lenalidomide is active for extramedullary disease in refractory multiple myeloma

By Nakazato Tomonori Mihara Ai Ito Chisako Sanada Yukinari Aisa Yoshinobu

Annals of Hematology, Vol. 91, Iss. 3, 2012-03 ,pp. : 473-474

Springer Publishing Company

Access to resources Recommend Favorite

Minimal Residual Disease in Hairy-cell Leukemia after Treatment with 2-chlorodeoxyadenosine

By Konwalinka G. Schirmer M. Hilbe W. Fend F. Geisen F. Knoblechner A. Petzer A. Thaler J.

Blood Cells, Molecules, and Diseases, Vol. 21, Iss. 2, 1995-08 ,pp. : 142-151

Academic Press

Access to resources Recommend Favorite

Flow cytometry in immunohematology

By Gane P.

Transfusion Clinique et Biologique, Vol. 9, Iss. 4, 2002-10 ,pp. : 271-279

Elsevier

Access to resources Recommend Favorite